Archives: Speakers

Jasmine Begin, M.S. RAC is the Director of Regulatory Affairs and Quality Assurance at Zosano Pharma.  She has worked on small molecule and drug/device combination products for over 15 years as a regulatory and quality assurance professional. In her current position, she manages the regulatory department providing strategic and operational guidance for investigational and filed products. Prior to Zosano Pharma, she has worked in small to large companies such as Depomed, Carbylan Therapeutics and IQVIA. Previously, her role in IQVIA was client facing to facilitate and deliver regulatory strategy to support new and lifecycle products.

Experienced biopharmaceutical executive with more than 20 years of clinical drug development and medical affairs experience in small to large pharmaceutical and biotechnology companies. I currently apply my scientific knowledge and experience to the development of molecules modulating the Wnt pathway.

Trudy served on the board of Insys Therapeutics from April 2018-February 2020 and is open to new board positions that leverage her R&D and corporate development experience.

Toby Odenheim is the former Director of Technology and Governance at the Parker Institute for Cancer Immunotherapy (PICI). He is now Senior Vice President, Research & Development Technology at ProPharma Group.

Committed to accelerating the development of new medical treatments through effective technology adoption and continual process improvement.

Nanomed, with the headquarter at Cupertino, CA, applies innovative microfabrication technology to make a delivery tool for skincare actives. This is a new way of overcoming skin barrier and delivering actives without needle injection.

The product successfully went through two clinical trials and got into the finals of Asian Innovation Award together with IBM Healthsolution Lab’s product sponsored by the Wall Street Journal and won Silver Prize in 2010.

Nanomed’s antiblemish product was successfully launched at AAD, the largest dermatology annual meeting in US. Together with Sephora’s product, Nanomed’s delivery product got into the top three for the International Package Design Award (tool category) at 2012 HBA Global in New York City.

Connecting LEO Pharma with startups, hi-tech companies and best-in-class research teams in Silicon Valley.

I have more than 10 years of experience in different sectors -Consulting, Banking, Petroleum, Insurance, Consumer Goods, Health Care and Technology, and strong international exposure (LATAM, North America, Europe and Middle East).

I learn fast and enjoy interacting with people in problem solving situations with high uncertainty. I am constantly interested in helping to solve business problems as well as mixing practices from different industries to solve innovation challenges.

Christina’s breadth of experience and understanding of clinical research comes from working throughout healthcare and clinical research in academics, medical institutions, local government (public health), and the medical device industry. She is the Director of Clinical Affairs at ReCor Medical, a Palo-Alto based company studying an ultrasound-based renal denervation technology to treat hypertension. She thrives on being challenged, creative and innovative while building highly effective and impactful clinical teams. She enjoys mentoring and leading others positively through her actions and energy.

Areas of Interest: Leadership, Clinical Research, Trial Management, Monitoring, Health Education, Project Management, Lecturer, Epidemiology, Public Health, Certified Clinical Research Associate, Leading remote and in-house teams.

Robert sits on various Finance & Leasing Association (hyperlink) committees as well as being deputy Chairman of the Asset Finance Professionals Association (again hyperlink) which is the UK’s Asset Finance industry charity and is a Founder Fellow of The Leasing Foundation (again hyperlink). Robert has previously sat on the Board of several major UK Charities including the National Autistic Society and Arts for All and is currently a main Patron of The Royal Albert Hall.

Robert is responsible for growing and expanding LTi business throughout the UK, Nordics and Europe.

Gale McCandlish is an experienced Quality Assurance professional with an extensive background in GCP and GLP compliance for both pharmaceutical companies and CROs. In her current role as Associate Director, Vendor Compliance at Gilead Sciences, Ms. McCandlish is accountable for GCP vendor risk management and audit strategy.  During the COVID-19 pandemic, Gale authored a remote audit process to ensure the continuation of vendor audit oversight responsibilities when onsite audits are not feasible.

Gale holds a BS in Biology from Bemidji State University and completed graduate work towards an MS in Biology from The George Washington University

• Formerly Global Head of Asset Management and Remarketing at DLL one of the world’s premier leasing companies.
• Ian brings vast experience of all aspects of asset management and is expert in equipment risk management and development of circular economic models.
• Prior to DLL, Ian worked for Dell Financial Services, CIT and Siemens Financial Services and is highly experienced in all aspects of vendor and direct leasing.
• Ian is an engineer by training as is a graduate of Manchester and Cambridge Universities in the UK.
• He is an industry leader capable of bridging between high level business strategy and the practicalities of systems, risk management, information management, process development, organizational delivery.
• Ian is regularly called on by clients to help develop their systems and technology ecosystems and has also helped several software vendors extend their value propositions.
• Originally a strategic business consultant he regularly supports OEMs and vendor finance companies in developing their business and financing strategies.